Pfizer Inc. (PFE) said, in 2021, the company exceeded its goal of manufacturing 3 billion doses of Comirnaty, the Pfizer-BioNTech COVID-19 vaccine. Looking forward, the company increased its 2022 revenue guidance for Comirnaty, reflecting doses expected to be delivered under supply contracts signed as of late-January. Also, the company issued fiscal guidance for the coming year which, if achieved, would represent the highest level of annual revenues and adjusted EPS in its history.
Pfizer also issued its long-term expectations for COVID-19. The company said the virus is able to mutate often, making it difficult to stay ahead of it. People can become reinfected by the same or different strains over time, the company noted.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.